Description
HLA-DR Antibody (MHC II) | V2583-20UG | Gentaur US, UK & Europe Disrtribition
Family: Primary antibody
Formulation: 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Format: Purified
Clone: IPO-10
Host Animal: Mouse
Clonality: Monoclonal (mouse origin)
Species Reactivity: Human
Application: FACS, IF
Buffer: N/A
Limitation: This HLA-DR antibody is available for research use only.
Purity: Protein G affinity chromatography
Description: mAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The mAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This mAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.
Immunogen: Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the HLA-DR antibody.
Storage: Store the HLA-DR antibody at 2-8oC (with azide) or aliquot and store at -20 °C or colder (without azide).
